Company
GelMEDIX
GelMEDIX is developing therapies that restore vision loss by regenerating damaged retinal cells and preserving the essential structures required for sight.
- Status
- Operatingas of 2026-09-19
- Founded
- 2020
Claim, correct or request removal
Record updated 19 September 2026
About
Our groundbreaking biomaterials technology has unlocked a new approach to optimize the delivery, efficacy, and safety of cell and gene therapies. GelMEDIX programs are based on our proprietary injectable hydrogel scaffold that we have engineered to improve the functional replacement and integration of therapeutic cells and the delivery of gene therapies.
Funding snapshot
- Total raised
- $13MSum of rounds, as of 2026-09-19Source (opens in a new tab)
- Latest round
- Seed, $13M2026-02-17
Funding rounds
- Seed
- $13M2026-02-17, Company stated
Products
- Other
- GMX-101
Loading relationship preview